John Renger - 05 Jul 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Chief Scientific Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
CERE
Transactions as of
05 Jul 2022
Transactions value $
-$694,545
Form type
4
Filing time
07 Jul 2022, 16:06:48 UTC
Previous filing
15 Apr 2022
Next filing
22 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $87.5K +25K +924.56% $3.50* 27.7K 05 Jul 2022 Direct F1, F2
transaction CERE Common Stock Sale -$750K -25K -90.24% $30.00 2.7K 05 Jul 2022 Direct F1
transaction CERE Common Stock Options Exercise $3.87K +1.11K +40.87% $3.50* 3.81K 06 Jul 2022 Direct F1
transaction CERE Common Stock Sale -$35.9K -1.11K -29.01% $32.50 2.7K 06 Jul 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -25K -13.1% $0.00 166K 05 Jul 2022 Common Stock 25K $3.50 Direct F1, F3
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -1.11K -0.67% $0.00 165K 06 Jul 2022 Common Stock 1.11K $3.50 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2 Includes 724 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2022.
F3 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.